12 new oncology trials approved in Europe
 |
Oncology Hero |
12 new oncology trials approved in Europe
Good morning, here is a concise selection of oncology and haematology trials and investigator opportunities in Europe.
EORTC-2456-LCG-BTG: A randomized phase II study evaluating upfront SRT to all brain metastases followed by ivonescimab plus chemotherapy versus upfront ivonescimab plus chemotherapy in patients with asymptomatic active brain metastases from NSCLC.
| Sponsor: European Organisation For Research And Treatment Of Cancer | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestBioavailability and Bioequivalence Study of Ziftomenib in Participants with Relapsed/Refractory AML or MDS
| Sponsor: Kura Oncology Inc. | Phase: |
Interested in offering this trial to suitable patients?
Register Investigator InterestDYNAMIC: randomised phase II sequencing strategies in driver-altered advanced non-small-cell lung cancer
| Sponsor: Universita' Degli Studi Di Torino | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestThe VIOLET Trial: A Pragmatic Phase II Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2− Early Breast Cancer Using Oncotype DX and Abemaciclib
| Sponsor: Istituto Di Ricerche Farmacologiche Mario Negri | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestPhase 2, open-label, randomized study to investigate safety and efficacy of Pluvicto® therapy in patients with metastatic hormone-sensitive prostate cancer in addition to standard of care treatment with Nubeqa® and ADT (ARALU)
| Sponsor: Medical Center - University Of Freiburg | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA Randomized, Open-label, Phase 3 Trial of Petosemtamab in Combination With mFOLFOX6 or FOLFIRI Versus Cetuximab in Combination With mFOLFOX6 or FOLFIRI as First-line Treatment for Participants With RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.
| Sponsor: Genmab A/S | Phase: 3 |
Interested in offering this trial to suitable patients?
Register Investigator InterestFirst-in-human phase I/II dose-escalation and randomized dose-optimization study of SOT109 in advanced colorectal cancer
| Sponsor: SOTIO Biotech a.s. | Phase: 1, 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestPHENIX: Anti-HER2 treatment discontinuation guided by circulating tumor DNA in HER2-positive metastatic breast cancer with sustained disease control
| Sponsor: Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)
| Sponsor: Verastem Inc. | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestPATRICIA-3 - A phase Ib/II chemotherapy-free trial evaluating zongertinib in combination with ribociclib, endocrine therapy and trastuzumab in patients with ER-positive/HER2-positive metastatic breast cancer
| Sponsor: Solti Group | Phase: 1, 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestPhase I first-in-human dose-escalation trial of ARI-HER2 (HER2BBz CAR-T cells) in HER2-positive advanced breast cancer
| Sponsor: Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer | Phase: 1 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA Phase 2, Open-label, Multicenter Study to Determine the Safety, Tolerability, and Efficacy of MK-1045 in Participants with Hematologic Malignancies
| Sponsor: Merck Sharp & Dohme LLC | Phase: 2 |
Not accepting new sites
Oncology Hero Trial Feed connects oncology professionals with relevant clinical trials.
For qualified healthcare and research professionals. Registration expresses investigator interest; it is not patient enrollment.
Oncology Hero
Sharing the latest updates in oncology
Oncology Hero 11 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials recently authorised in Europe. A phase II, multicenter, open-label, personalized medicine, tumor agnostic platform trial evaluating the anti-tumor activity of antibody-based therapies in metastatic cancer patients Sponsor: Centre Leon Berard Phase: 2 Interested in offering this trial to suitable patients? Register Investigator Interest PD-1 blockade alone versus...
Oncology Hero 8 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials recently authorised in Europe. Breast density reduction with linzagolix or bilastine in premenopausal women at high risk of breast cancer: a phase II clinical trial. Sponsor: Consorci Mar Parc De Salut De Barcelona Phase: 2 Interested in offering this trial to suitable patients? Register Investigator Interest A phase 2 study to assess efficacy of induction...
Oncology Hero 8 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials recently authorised in Europe. RINGQUEST: Exploring Understudied Genitourinary Tumors with Sacituzumab Tirumotecan; a Single-arm, Basket, Phase II Study. Sponsor: Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard Phase: 2 Interested in offering this trial to suitable patients? Register Investigator Interest [18F] MC225 PET...